Innovating Works

ReSpire

Financiado
Respirable Advanced Therapeutics for Cystic Fibrosis other Lung Diseases
Via the SME Instrument OmniSpirant Ltd will mature its stem cell exosome-packaged gene therapy with lung mucus penetration properties which will be more effective (improved lung function, reversal of lung damage and superior CFTR... Via the SME Instrument OmniSpirant Ltd will mature its stem cell exosome-packaged gene therapy with lung mucus penetration properties which will be more effective (improved lung function, reversal of lung damage and superior CFTR gene expression and function) and also be applicable to 100% of the CF global population. This approach, using a combined patent pending exosome surface engineering for enhanced mucus penetration and cell transfection with a tailored vibrating mesh nebulisation aerosol delivery method will provide a unique, potentially disruptive, therapeutic modality for CF and many other lung diseases with high unmet medical need. Our competitive advantage and Unique Selling Points lower current effectiveness barriers and make the OmniSpirant exosome technology the only therapeutic delivery method that could provide a truly effective treatment for CF, thus improving both survival rates the quality of life of CF suffers. Importantly, the quality of life for CF patients will increase to point where they are able to work. The OmniSpirant system will, over time, be regarded as an essential weapon in the armoury of health systems in the battle against other serious respiratory conditions affecting major patient populations such as lung cancer and COPD, globally. The overall objective of our feasibility study is to demonstrate the potential value of the combined gene therapy system maturation based on a comprehensive analysis of the business concept in terms of technical, commercial and financial viability. The outcome of the study will be a full Business Plan that will feed into a Phase 2 project. ver más
31/07/2019
71K€
Duración del proyecto: 6 meses Fecha Inicio: 2019-01-28
Fecha Fin: 2019-07-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-07-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 71K€
Líder del proyecto
OMNISPIRANT LIMITED No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5